Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Whilst GLP-1 agonists are not licensed for treating depression and evidence remains preliminary, their effects on brain regions involved in mood regulation have sparked considerable scientific interest
Start by speaking to your GP, who can assess your individual circumstances and refer you to appropriate NHS weight management services, including structured lifestyle programmes or specialist tier 3 or tier 4 services for complex cases
May 2021.
Note: A 2023 SELECT trial showed semaglutide reduced the risk of major heart attacks and strokes by 20% in obese patients independent of weight loss
The peptide stacking guide covers general principles for combining peptides, and the peptide stack calculator helps model multi-peptide protocols
Statements from the FDA About Ozempic On October 2, 2024, the FDA issued a postmarket safety information statement about concerns with unapproved versions of GLP-1 receptor agonists used for weight loss
